Abstract
Loss of function mutations and deletions encompassing the plant homeodomain finger 6 (PHF6) gene are present in about 20% of T-cell acute lymphoblastic leukemias (ALLs). Here, we report the identification of recurrent mutations in PHF6 in 10/353 adult acute myeloid leukemias (AMLs). Genetic lesions in PHF6 found in AMLs are frameshift and nonsense mutations distributed through the gene or point mutations involving the second plant homeodomain (PHD)-like domain of the protein. As in the case of T-ALL, where PHF6 alterations are found almost exclusively in males, mutations in PHF6 were seven times more prevalent in males than in females with AML. Overall, these results identify PHF6 as a tumor suppressor gene mutated in AML and extend the role of this X-linked tumor suppressor gene in the pathogenesis of hematologic tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915–931.
Dohner K, Dohner H . Molecular characterization of acute myeloid leukemia. Haematologica 2008; 93: 976–982.
Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838–842.
Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113: 6403–6410.
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.
Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66–72.
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.
Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol; 28: 2348–2355.
Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010; 116: 614–616.
Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010; 42: 338–342.
Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 2003; 102: 1000–1006.
Bohlander SK, Muschinsky V, Schrader K, Siebert R, Schlegelberger B, Harder L et al. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia 2000; 14: 93–99.
Quentmeier H, Schneider B, Rohrs S, Romani J, Zaborski M, Macleod RA et al. SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol 2009; 2: 3.
Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008; 111: 4668–4680.
Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003; 102: 262–268.
Bos JL, Toksoz D, Marshall CJ, Verlaan-de Vries M, Veeneman GH, van der Eb AJ et al. Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 1985; 315: 726–730.
Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res 1999; 23: 115–126.
Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009; 113: 5951–5960.
Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S et al. WT1 mutations in T-ALL. Blood 2009; 114: 1038–1045.
Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997; 11: 1442–1446.
Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004; 104: 558–560.
Van Vlierberghe P, Meijerink JP, Stam RW, van der Smissen W, van Wering ER, Beverloo HB et al. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. Blood 2005; 106: 4414–4415.
Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008; 111: 4322–4328.
Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell Mar 16; 17: 225–234.
Aifantis I, Feinberg J, Fehling HJ, Di Santo JP, von Boehmer H . Early T cell receptor beta gene expression is regulated by the pre-T cell receptor-CD3 complex. J Exp Med 1999; 190: 141–144.
Voss AK, Gamble R, Collin C, Shoubridge C, Corbett M, Gecz J et al. Protein and gene expression analysis of Phf6, the gene mutated in the Borjeson-Forssman-Lehmann syndrome of intellectual disability and obesity. Gene Expr Patterns 2007; 7: 858–871.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.
Lower KM, Turner G, Kerr BA, Mathews KD, Shaw MA, Gedeon AK et al. Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat Genet 2002; 32: 661–665.
Borjeson M, Forssman H, Lehmann O . An X-linked, recessively inherited syndrome characterized by grave mental deficiency, epilepsy, and endocrine disorder. Acta Med Scand 1962; 171: 13–21.
Turner G, Lower KM, White SM, Delatycki M, Lampe AK, Wright M et al. The clinical picture of the Borjeson-Forssman-Lehmann syndrome in males and heterozygous females with PHF6 mutations. Clin Genet 2004; 65: 226–232.
Chao M, Todd MA, Kontny U, Neas K, Sullivan MJ, Hunter AG et al. T-cell acute lymphoblastic leukemia in association with Börjeson-Forssman-Lehmann syndrome due to a mutation in PHF 6. Pediatr Blood Cancer 2010; 55: 722–724.
Acknowledgements
This study was supported by the Fund for Scientific Research (FWO) Flanders (postdoctoral grants to PVV and project grants G.0198.08 and G.0869.10N to FS); the GOA-UGent (Grant no. 12051203); the IWT-Vlaanderen (SBO Grant no. 060848); the Children Cancer Fund Ghent (FS); the Belgian Program of Interuniversity Poles of Attraction; the Belgian Foundation Against Cancer; the ECOG and MSKCC tumor banks; a Physical Sciences-Oncology Center grant from the NCI (RLL); the National Institutes of Health (R01CA120196 and R01CA129382 to AF); the Rally Across America Foundation (AF); the Swim Across America Foundation (AF) and the Golfers Against Cancer Foundation (AF). RLL is the Geoffrey Beene Junior Chair and an Early Career Award Recipient of the Howard Hughes Medical Institute. AF is a Leukemia and Lymphoma Society Scholar. We appreciate the assistance of Adriana Heguy with DNA resequencing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
PVV performed mutation analysis of PHF6 and wrote the manuscript. JP, OA and RL performed mutation analysis of PHF6 on the ECOG patient series (E1900). CL and IA performed the isolation of murine hematopoietic stem cell (HSC) and myeloid progenitor populations. EP and AM provided samples and correlative data from ECOG. MB, CN and AP provided samples and correlative data from Hospital Central de Asturias. PV, JC and FS provided samples and correlative data from the University Hospital Leuven. RL and CH provided samples and correlative data from MSKCC. AF designed the studies, directed research and wrote the manuscript.
Rights and permissions
About this article
Cite this article
Van Vlierberghe, P., Patel, J., Abdel-Wahab, O. et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia 25, 130–134 (2011). https://doi.org/10.1038/leu.2010.247
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.247
Keywords
This article is cited by
-
PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model
Cancer Cell International (2024)
-
PHF6 maintains acute myeloid leukemia via regulating NF-κB signaling pathway
Leukemia (2023)
-
The Role of PHF6 in Hematopoiesis and Hematologic Malignancies
Stem Cell Reviews and Reports (2023)
-
Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair
Oncogene (2022)
-
Epigenetic reversal of hematopoietic stem cell aging in Phf6-knockout mice
Nature Aging (2022)